ARWR Insider Trading

Insider Ownership Percentage: 4.50%
Insider Buying (Last 12 Months): $54,990.00
Insider Selling (Last 12 Months): $6,505,093.18

Arrowhead Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Arrowhead Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$2.01MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

Arrowhead Pharmaceuticals Share Price & Price History

Current Price: $19.98
Price Change: Price Decrease of -0.255 (-1.26%)
As of 01/31/2025 01:43 PM ET

This chart shows the closing price history over time for ARWR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$20.23Closing price on 01/30/25:

SEC Filings (Institutional Ownership Changes) for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

62.61% of Arrowhead Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARWR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.65Mbought$5.07MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Read More on Arrowhead Pharmaceuticals

Today's Range

Now: $19.98
Low: $19.90
High: $20.50

50 Day Range

MA: $20.85
Low: $18.05
High: $26.34

52 Week Range

Now: $19.98
Low: $17.05
High: $36.72

Volume

240,262 shs

Average Volume

2,650,625 shs

Market Capitalization

$2.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Who are the company insiders with the largest holdings of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' top insider shareholders include:
  1. Christopher Richard Anzalone (CEO)
  2. Patrick O'brien (COO)
  3. Kenneth Allen Myszkowski (CFO)
  4. James C Hamilton (Insider)
  5. Martin Javier San (Insider)
  6. Douglas B Given (Director)
  7. Tracie Oliver (Insider)
  8. William D Waddill (Director)
  9. Adeoye Y Olukotun (Director)
  10. Hongbo Lu (Director)
  11. Victoria Vakiener (Director)
Learn More about top insider investors at Arrowhead Pharmaceuticals.

Who are the major institutional investors of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' top institutional shareholders include:
  1. abrdn plc — 0.36%
  2. Rhumbline Advisers — 0.31%
  3. Principal Financial Group Inc. — 0.23%
  4. Wealth Effects LLC — 0.13%
  5. Nordea Investment Management AB — 0.11%
  6. State of New Jersey Common Pension Fund D — 0.09%
Learn More about top institutional investors of Arrowhead Pharmaceuticals stock.

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

During the last quarter, ARWR stock was sold by these institutional investors:
  1. Assenagon Asset Management S.A.
  2. Wealth Effects LLC
  3. Exchange Traded Concepts LLC
  4. Yousif Capital Management LLC
  5. Oak Ridge Investments LLC
  6. Principal Financial Group Inc.
In the last year, company insiders that have sold Arrowhead Pharmaceuticals company stock include:
  1. Christopher Richard Anzalone (CEO)
  2. Patrick O'brien (COO)
  3. Kenneth Allen Myszkowski (CFO)
  4. James C Hamilton (Insider)
  5. Martin Javier San (Insider)
  6. Douglas B Given (Director)
  7. Tracie Oliver (Insider)
  8. William D Waddill (Director)
Learn More investors selling Arrowhead Pharmaceuticals stock.

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

Within the last quarter, ARWR stock was acquired by institutional investors including:
  1. abrdn plc
  2. State of New Jersey Common Pension Fund D
  3. Empowered Funds LLC
  4. First Citizens Bank & Trust Co.
  5. Rhumbline Advisers
  6. Nordea Investment Management AB
  7. Pacer Advisors Inc.
  8. China Universal Asset Management Co. Ltd.